NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Part of paid clinical trials in Bradenton, Florida.
- Sponsor
- Agomab Spain S.L.U.
- Study ID
- NCT07683325
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Fibrostenotic Crohn's Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ontunisertib — DRUGOral capsule
- Ontunisertib — DRUGOral capsule
- Ontunisertib — DRUGOral capsule
- Placebo — DRUGMatching oral capsule
Study Details
Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD). The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.
Key Dates
- First listed
- Jul 6, 2026
- Start date
- Oct 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2028
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 320 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ontunisertib HighOntunisertib high dose
- Experimental: Ontunisertib MediumOntunisertib medium dose
- Experimental: Ontunisertib LowOntunisertib low dose
- Experimental: PlaceboMatching placebo
Primary Outcome Measure
Proportion of participants achieving endoscopic passability of the ileal index stricture [ Time Frame: At week 24 ]
Central Contacts
- Agomab Clinical Operations0032 3318 91 70
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Synergy Healthcare, LLC | Bradenton | Florida | 34209 | - |